We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+5.04%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$363M
AUM Growth
-$5.41M
Cap. Flow
+$2.38M
Cap. Flow %
0.66%
Top 10 Hldgs %
7.17%
Holding
495
New
34
Increased
285
Reduced
131
Closed
45

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$2.11M
2
HSY icon
Hershey
HSY
+$2.09M
3
GILD icon
Gilead Sciences
GILD
+$2.07M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$2.05M
5
EIX icon
Edison International
EIX
+$2.04M

Top Sells

Rank Stock Value
1
HBAN icon
Huntington Bancshares
HBAN
+$2.13M
2
TKO icon
TKO Group
TKO
+$2.13M
3
WAT icon
Waters Corp
WAT
+$2.09M
4
STT icon
State Street
STT
+$2.07M
5
AON icon
Aon
AON
+$2.04M

Sector Composition

Rank Sector Weight
1 Healthcare 31.87%
2 Financials 20.97%
3 Technology 10.66%
4 Industrials 10.62%
5 Consumer Discretionary 7.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OXSQ icon
251
Oxford Square Capital
OXSQ
$152M
$378K 0.1%
213,488
-9,248
-4% -$16.7K
ORIC icon
252
Oric Pharmaceuticals
ORIC
$1.25B
$368K 0.1%
29,069
+708
+2% +$8.04K
VIR icon
253
Vir Biotechnology
VIR
$1.46B
$365K 0.1%
40,759
+995
+3% +$7.93K
EWTX icon
254
Edgewise Therapeutics
EWTX
$4.38B
$364K 0.1%
11,544
+281
+2% +$8.1K
NCDL icon
255
Nuveen Churchill Direct Lending
NCDL
$598M
$363K 0.1%
28,562
+1,107
+4% +$14.9K
XENE icon
256
Xenon Pharmaceuticals
XENE
$6.32B
$360K 0.1%
6,188
+151
+3% +$6.96K
NKTR icon
257
Nektar Therapeutics
NKTR
$2.4B
$359K 0.1%
4,984
+121
+2% +$6.89K
PCVX icon
258
Vaxcyte
PCVX
$7.89B
$356K 0.1%
6,126
+147
+2% +$7.98K
PVLA
259
Palvella Therapeutics
PVLA
$1.98B
$345K 0.1%
2,765
+67
+2% +$6.99K
MLTX icon
260
MoonLake Immunotherapeutics
MLTX
$1.59B
$344K 0.09%
18,436
+449
+2% +$7.44K
TPVG icon
261
TriplePoint Venture Growth BDC
TPVG
$181M
$342K 0.09%
68,513
-1,069
-2% -$6.1K
RLAY icon
262
Relay Therapeutics
RLAY
$4.01B
$338K 0.09%
33,957
+827
+2% +$7.4K
ANAB icon
263
AnaptysBio
ANAB
$1.6B
$336K 0.09%
6,067
+148
+3% +$7.96K
RVMD icon
264
Revolution Medicines
RVMD
$40.2B
$336K 0.09%
3,454
+83
+2% +$8.38K
OFS icon
265
OFS Capital
OFS
$43.5M
$329K 0.09%
92,665
+10,444
+13% +$43.8K
PRAX icon
266
Praxis Precision Medicines
PRAX
$9.06B
$326K 0.09%
1,013
+24
+2% +$7.42K
CGEM icon
267
Cullinan Oncology
CGEM
$1.05B
$325K 0.09%
22,875
+557
+2% +$7.16K
TERN
268
DELISTED
Terns Pharmaceuticals
TERN
$319K 0.09%
6,058
+146
+2% +$6K
PHVS icon
269
Pharvaris
PHVS
$2.39B
$319K 0.09%
11,286
+275
+2% +$7.34K
CAPR icon
270
Capricor Therapeutics
CAPR
$1.14B
$319K 0.09%
10,479
+255
+2% +$6.79K
CLDX icon
271
Celldex Therapeutics
CLDX
$2.77B
$314K 0.09%
9,911
+240
+2% +$6.54K
LQDA icon
272
Liquidia Corp
LQDA
$7.67B
$308K 0.09%
8,169
+200
+3% +$7.42K
BLTE
273
Belite Bio
BLTE
$6.16B
$308K 0.08%
1,929
+47
+2% +$7.9K
CTMX icon
274
CytomX Therapeutics
CTMX
$705M
$306K 0.08%
65,080
+1,589
+3% +$8.07K
IMNM icon
275
Immunome
IMNM
$2.52B
$305K 0.08%
13,932
+339
+2% +$7.54K
9 10
11
12 13

Similar funds

RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
MA
Modus Advisors Excelsior, Minnesota $363M AUM 22.99% 1-Year Est. Return

Virtus Investment Advisers's Q1 2026 Portfolio in Review

As of Q1 2026, Virtus Investment Advisers held 495 positions worth $363M, down 1.5% from $368M the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.

Virtus Investment Advisers's Q1 2026 filing shows 34 new, 285 increased, 131 reduced and 45 closed positions. Its largest new stake was Hershey: 9,903 shares worth $2.06M. The largest sale was Huntington Bancshares, an estimated $2.13M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 27% a quarter earlier, followed by Financials and Technology.

  • Virtus Investment Advisers's largest Q1 2026 buy was Hershey: 9,903 shares worth $2.06M.
  • Virtus Investment Advisers added most to Amgen in Q1 2026, an estimated $2.11M increase.
  • Virtus Investment Advisers's biggest Q1 2026 reduction was Micron Technology, cutting an estimated $1.56M.
  • Virtus Investment Advisers fully exited Huntington Bancshares in Q1 2026, selling an estimated $2.13M.
  • Virtus Investment Advisers's ten largest holdings make up 7.2% of its $363M portfolio in Q1 2026.
  • Virtus Investment Advisers opened 34 new positions and closed 45 in Q1 2026.
  • Virtus Investment Advisers's portfolio value fell 1.5% quarter-over-quarter to $363M.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.